Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (569)	2/14/1999 2:37:00 PM
From: BRAVEHEART	Read Replies (1) \| Respond to of 1073

Hi Richard, Ongoing concerns for third tier biotech's is and always will be the issue of funding operations. Lately ARIA and PARS has come under the convertible financing knife. I am all too familiar with many other companies which have undergone similar financings. Peter Suzman has shared a very insightful article on this process from a legal perspective at another thread. From the National Law Journal on floorless instruments: ljx.com I would like to further that understanding by suggesting that one should have a thorough appreciation for the CFO of an organization. That one should also come to better appreciate and understand the stages of funding biotech. Nature Biotechnology recently included a very insightful supplement on Bioentrepreneurship. It has several interesting articles on the financing of biotech and how it relates to risk. This gives a nice overview of proper funding strategies which should be useful to individual investors in making decisions where to invest. Rick while I know you subscribe to Nature I would implore others who do not to at least get ahold of the Feb issue and it's supplement. Just in case you are considering a subscription: old.biotech.nature.com BEST WISHES LONE WOLF